174 related articles for article (PubMed ID: 37530674)
1. Fifty years of research on mitochondrial fatty acid oxidation disorders: The remaining challenges.
Vianey-Saban C; Guffon N; Fouilhoux A; Acquaviva C
J Inherit Metab Dis; 2023 Sep; 46(5):848-873. PubMed ID: 37530674
[TBL] [Abstract][Full Text] [Related]
2. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.
Lindner M; Hoffmann GF; Matern D
J Inherit Metab Dis; 2010 Oct; 33(5):521-6. PubMed ID: 20373143
[TBL] [Abstract][Full Text] [Related]
3. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
Vockley J; Charrow J; Ganesh J; Eswara M; Diaz GA; McCracken E; Conway R; Enns GM; Starr J; Wang R; Abdenur JE; Sanchez-de-Toledo J; Marsden DL
Mol Genet Metab; 2016 Nov; 119(3):223-231. PubMed ID: 27590926
[TBL] [Abstract][Full Text] [Related]
4. Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders.
Sim KG; Hammond J; Wilcken B
Clin Chim Acta; 2002 Sep; 323(1-2):37-58. PubMed ID: 12135806
[TBL] [Abstract][Full Text] [Related]
5. Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program.
Vockley J; Enns GM; Ramirez AN; Bedrosian CL; Reineking B; Lu X; Ray K; Rahman S; Marsden D
Mol Genet Metab; 2022 Jun; 136(2):152-162. PubMed ID: 35459555
[TBL] [Abstract][Full Text] [Related]
6. Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program.
Yang E; Kruger E; Yin D; Mace K; Tierney M; Liao N; Cibelli E; Drozd D; Ross N; Deering KL; Herout P; Harshaw Q; Shillington A; Thomas N; Marsden D; Kritzer A; Vockley J
Mol Genet Metab; 2024 May; 142(1):108350. PubMed ID: 38458123
[TBL] [Abstract][Full Text] [Related]
7. Clinical manifestations and management of fatty acid oxidation disorders.
Merritt JL; MacLeod E; Jurecka A; Hainline B
Rev Endocr Metab Disord; 2020 Dec; 21(4):479-493. PubMed ID: 32654032
[TBL] [Abstract][Full Text] [Related]
8. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
[TBL] [Abstract][Full Text] [Related]
9. Selective Screening of Fatty Acids Oxidation Defects and Organic Acidemias by Liquid Chromatography/tandem Mass Spectrometry Acylcarnitine Analysis in Brazilian Patients.
Vargas CR; Ribas GS; da Silva JM; Sitta A; Deon M; de Moura Coelho D; Wajner M
Arch Med Res; 2018 Apr; 49(3):205-212. PubMed ID: 30119976
[TBL] [Abstract][Full Text] [Related]
10. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Humphrey R; Mayhew J; Bowden A; Zhang L; Cataldo J; Marsden DL; Kakkis E
Mol Genet Metab; 2017 Apr; 120(4):370-377. PubMed ID: 28189603
[TBL] [Abstract][Full Text] [Related]
11. Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders.
Zöggeler T; Stock K; Jörg-Streller M; Spenger J; Konstantopoulou V; Hufgard-Leitner M; Scholl-Bürgi S; Karall D
Orphanet J Rare Dis; 2021 Jan; 16(1):28. PubMed ID: 33446227
[TBL] [Abstract][Full Text] [Related]
12. Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation.
McCoin CS; Piccolo BD; Knotts TA; Matern D; Vockley J; Gillingham MB; Adams SH
J Inherit Metab Dis; 2016 May; 39(3):399-408. PubMed ID: 26907176
[TBL] [Abstract][Full Text] [Related]
13. Long-chain fatty acid oxidation disorders and current management strategies.
Vockley J
Am J Manag Care; 2020 Aug; 26(7 Suppl):S147-S154. PubMed ID: 32840329
[TBL] [Abstract][Full Text] [Related]
14. A review of fatty acid oxidation disorder mouse models.
Babcock SJ; Houten SM; Gillingham MB
Mol Genet Metab; 2024 May; 142(1):108351. PubMed ID: 38430613
[TBL] [Abstract][Full Text] [Related]
15. Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long-chain fatty acid oxidation disorders.
McCoin CS; Gillingham MB; Knotts TA; Vockley J; Ono-Moore KD; Blackburn ML; Norman JE; Adams SH
Physiol Rep; 2019 Mar; 7(6):e14037. PubMed ID: 30912279
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.
Spiekerkoetter U
J Inherit Metab Dis; 2010 Oct; 33(5):527-32. PubMed ID: 20449660
[TBL] [Abstract][Full Text] [Related]
17. Triheptanoin: First Approval.
Shirley M
Drugs; 2020 Oct; 80(15):1595-1600. PubMed ID: 32897506
[TBL] [Abstract][Full Text] [Related]
18. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.
Spiekerkoetter U; Bastin J; Gillingham M; Morris A; Wijburg F; Wilcken B
J Inherit Metab Dis; 2010 Oct; 33(5):555-61. PubMed ID: 20830526
[TBL] [Abstract][Full Text] [Related]
19. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
Vockley J; Burton B; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman K; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Cataldo J
J Inherit Metab Dis; 2021 Jan; 44(1):253-263. PubMed ID: 32885845
[TBL] [Abstract][Full Text] [Related]
20. The inborn errors of mitochondrial fatty acid oxidation.
Vianey-Liaud C; Divry P; Gregersen N; Mathieu M
J Inherit Metab Dis; 1987; 10 Suppl 1():159-200. PubMed ID: 3119938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
